Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic ...
CHMP recommends Dupixent for EoE in children aged 1-11, based on Phase 3 trial showing histological remission. If approved, it would be the first EU treatment for this age group.
Dupixent® (dupilumab) Recommended for EU Approval by the
CHMP recommends Dupixent for EoE in children aged 1-11, based on Phase 3 trial showing histological remission. If approved, it would be the first EU treatment for this age group.
Hemophilia B Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. The analysis reveals AbbVie's high Price to Earnings (64.53), Price to Book (50.28), and Price to Sales (6.22) ratios, suggesting a potentially overvalued stock. However, its high Return on Equity (18.4%), EBITDA ($5.0B), and gross profit ($10.26B) indicate strong profitability and operational efficiency. The company's low revenue growth (4.31%) compared to the industry average (28.79%) raises concerns about future performance.
4DMT's Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies
4D Molecular Therapeutics' gene therapy 4D-150 showed durable clinical activity in Phase I/II PRISM study for wet AMD, reducing standard-of-care injections by 89% in 30 patients and 83% in 27 severe cases. The therapy was well-tolerated with a 2.8% incidence of intraocular inflammation. 4DMT plans to advance 4D-150 into Phase III 4FRONT program, targeting 500 patients starting Q1 2025.
Top three trends in precision medicine
Precision medicine uses genetic, environmental, and lifestyle data to tailor treatments, with AI, CRISPR-Cas9, and mRNA as key trends. AI accelerates genomic analysis and drug discovery, CRISPR-Cas9 offers precise gene editing, and mRNA vaccines expand beyond COVID-19, driving personalized healthcare.
Two targets, one solution: The rise of bispecific antibodies
Bispecific antibodies, with two binding domains, offer targeted therapeutics and address co-administration challenges, gaining traction in biopharma. Initially approved for cancer, they now target various diseases, with 12 approved in the U.S. and more in development. Their dual action reduces patient burden and enhances treatment effects, potentially transforming therapeutic paradigms beyond oncology. The market is projected to grow significantly due to rising chronic disease incidence and technological advancements.
FDA Approves Pavblu for Retinal Conditions
The FDA approved Pavblu (aflibercept-ayyh), the fifth Eylea biosimilar, for treating retinal conditions. Pavblu, developed by Amgen, showed no clinically meaningful differences in a phase 3 study compared to Eylea. Amgen and Regeneron are in a lawsuit over Pavblu's approval.
© Copyright 2024. All Rights Reserved by MedPath